Rania Rabie, Khalid Mumtaz, Eberhard L. Renner – 23 July 2012 – Cyclosporine A (CSA), but not tacrolimus (TAC), inhibits hepatitis C virus (HCV) replication in vitro. Clinical reports on the efficacy of interferon‐α (IFNα)–based antiviral therapy (AVT) for recurrent HCV after liver transplantation (LT) with CSA and TAC are conflicting. Our aim was to assess whether AVT for recurrent HCV after LT is more effective with CSA or TAC. We performed an electronic database search (1995‐2012) and a manual abstract search (2005‐2012).

Jason Schwartz, Heather Thiesset, Terry Box, William Hutson, John Sorensen – 23 July 2012

Qinggong Yuan, Komal Loya, Bhavna Rani, Selina Möbus, Asha Balakrishnan, Jutta Lamle, Toni Cathomen, Arndt Vogel, Michael P. Manns, Michael Ott, Tobias Cantz, Amar Deep Sharma – 23 July 2012 – The tightly controlled replication of hepatocytes in liver regeneration and uncontrolled proliferation of tumor cells in hepatocellular carcinoma (HCC) are often modulated by common regulatory pathways. Several microRNAs (miRNAs) are involved in HCC progression by modulating posttranscriptional expression of multiple target genes.

Diana L. Sylvestre – 23 July 2012 – Watch an interview with the author

Nezam H. Afdhal – 23 July 2012 – Watch a video presentation of this article

Mark S. Sulkowski – 23 July 2012 – Watch the interview with the author

Eric S. Orman, Michael W. Fried – 23 July 2012 – Watch the interview with the authors

Yasutsugu Takada, Yoshimi Suzukamo, Fumitaka Oike, Hiroto Egawa, Satoshi Morita, Shunichi Fukuhara, Shinji Uemoto, Koichi Tanaka – 20 July 2012 – The aims of this study were to investigate the long‐term effects of living donor liver transplantation (LDLT) on the health‐related quality of life (HRQOL) of donors with the Short Form 36 health survey and to determine the risk factors for poor outcomes. Between June 1990 and June 2004, LDLT was performed 1000 times at Kyoto University Hospital.

Surabhi Madhwal, Ashish Atreja, Mazen Albeldawdi, Rocio Lopez, Anthony Post, Marco A. Costa – 20 July 2012 – Up to two‐thirds of patients develop metabolic syndrome within the first 5 years after orthotopic liver transplantation (OLT). However, data on overall cardiovascular (CV) morbidity and mortality among OLT recipients and particularly those who develop metabolic syndrome remain elusive.

Da‐Qiang Li, Rakesh Kumar – 19 July 2012